Analysis of cytosine-adenine repeats in P1 promoter region of IGF-1 gene in peripheral blood cells and cervical tissue samples of females with cervical intraepithelial lesions and squamous cervical cancer

Kwasniewski,Wojciech; Gozdzicka‑Jozefiak,Anna; Kotarska,Maria; Polak,Grzegorz; Barczynski,Bartlomiej; Broniarczyk,Justyna; Nowak,Witold; Wolun‑Cholewa,Maria; Kwasniewska,Anna; Kotarski,Jan

doi:10.3892/mmr.2014.2916

Analysis of cytosine-adenine repeats in P1 promoter region of IGF-1 gene in peripheral blood cells and cervical tissue samples of females with cervical intraepithelial lesions and squamous cervical cancer

Authors:
- Wojciech Kwasniewski
- Anna Gozdzicka‑Jozefiak
- Maria Kotarska
- Grzegorz Polak
- Bartlomiej Barczynski
- Justyna Broniarczyk
- Witold Nowak
- Maria Wolun‑Cholewa
- Anna Kwasniewska
- Jan Kotarski
View Affiliations

Affiliations: Department of Gynecological Oncology and Gynecology, Medical University of Lublin, Lublin 20-081, Poland, Department of Molecular Virology, Adam Mickiewicz University, Poznan 61-614, Poland, Rush Medical College, Rush Medical Center, Chicago, IL 606-12, USA, Molecular Biology Techniques Laboratory, Adam Mickiewicz University, Poznan 61-614, Poland, Department of Cell Biology, Poznan University of Medical Sciences, Poznan 60-806, Poland, Department of Obstetrics and Gynecology, Medical University of Lublin, Lublin 20-081, Poland
Published online on: November 10, 2014 https://doi.org/10.3892/mmr.2014.2916
Pages: 766-774
Copyright: © Kwasniewski et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

High oncogenic risk human papillomaviruses (HPVs) are closely associated with cancer of the cervix. However, HPV infection alone may not be sufficient to cause cervical cancer, and other factors or cofactors may have a cumulative effect on the risk of progression from cervical HPV infection to cancer. The present study investigates the cytosine‑adenine (CA) repeat polymorphism in the P1 promoter region of the insulin‑like growth factor‑1 (IGF‑1) gene among cervical precancerous and cancer patients and healthy control females. The association between these polymorphisms, tissue and blood serum levels of IGF‑1, and cervical cancer risk and progression is evaluated. The material for analysis consisted of blood cells and postoperative tissues from patients diagnosed with low‑grade squamous intraepithelial lesions (L‑SILs), high‑grade squamous intraepithelial lesions (H‑SILs) and invasive cervical cancer (ICC). A polymerase chain reaction amplification and the sequencing of DNA were used for the identification of (CA)n repeats in the IGF‑1 P1 region and detection of HPV DNA. The blood serum concentration of IGF was determined by enzyme‑linked immunosorbent assay. The identification of the IGF‑1 protein in the cervical tissues was performed by immunohistochemical analysis. The range of the length of the CA repeats in the study DNA was 11 to 21. However, the most common allele length and genotype in the control and study patients from serum and tissues was 19 CA repeats and a homozygous genotype of CA19/19. Statistically significant differences in the concentration of IGF‑1 in the blood serum were observed between H‑SILs and controls, only (p=0.047). However, the concentration of IGF‑1 in the group of females with CA19/19, CA19<19 and CA19>19 was significantly higher in the group of patients with H‑SIL (P=0.041) and ICC (P=0.048) in comparison with the control group. An association was detected between CA repeat length <19 and/or >19, IGF concentration in blood serum and tissues and the development of cervical cancer.

View Figures

View References

1	Doorbar J: Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 110:525–541. 2006. View Article : Google Scholar
2	zur Hausen H: Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer. 2:342–350. 2002. View Article : Google Scholar : PubMed/NCBI
3	Rosenzwieg SA and Atreya HS: Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem Pharmacol. 80:1115–1124. 2010. View Article : Google Scholar
4	Baserga R: Customizing the targeting of IGF-1 receptor. Future Oncol. 5:43–53. 2009. View Article : Google Scholar : PubMed/NCBI
5	Weroha SJ and Haluska P: The insulin-like growth factor system in cancer. Endocrinol Metab Clin North Am. 41:335–350. 2012. View Article : Google Scholar : PubMed/NCBI
6	Laron Z, Steuerman R and Shevah O: Laron Syndrome patients with congenital IGF-I deficiency seem protected from malignant diseases. Laron Syndrome - From Man to Mouse. Laron Z and Kopchich J: Springer-Verlag; Berlin Heidelberg: pp. 339–340. 2011, View Article : Google Scholar
7	Grimberg A and Cohen P: Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol. 183:1–9. 2000. View Article : Google Scholar : PubMed/NCBI
8	Pollak MN: Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer. 12:915–928. 2008. View Article : Google Scholar
9	Rotwein P, Pollock KM, Didier DK and Krivi GG: Organization and sequence of the human insulin-like growth factor I gene. J Biol Chem. 261:4828–4832. 1986.PubMed/NCBI
10	Adamo ML, Neuenschwander S, LeRoith D, et al: Structure, expression and regulation of the IGF-I gene. Adv Exp Med Biol. 343–351. 1993.
11	Yu H, Li B, Smith M, et al: Polymorphic CA repeats in the IGF-I gene and breast cancer. Breast Cancer Res Treat. 70:117–122. 2001. View Article : Google Scholar
12	Wong HL, Delellis K, Probst-Hensch N, et al: A new single nucleotide polymorphism in the insulin-like growth factor I regulatory region associates with colorectal cancer risk in Singapore Chinese. Cancer Epidemiol Biomarkers Prev. 14:144–151. 2005.PubMed/NCBI
13	Chen X, Guan J, Song Y, et al: IGF I (CA) repeat polymorphism and risk of cancer: a meta analysis. J Hum Genet. 53:227–238. 2008. View Article : Google Scholar
14	Pacholska-Bogalska J, Jozefiak A, Nowak W, et al: Association of the IGF-I promoter P1 polymorphism with risk of cervical cancer. Eur J Gynaecol Oncol. 32:393–398. 2011.PubMed/NCBI
15	Tavassoli FA and Deville P: World Health Organization Classification of Tumors. Pathology, Genetics. Tumours of the Breast and Female Genital Organs. IRAC Press; Lyon: 2003
16	Benedet JL, Bender H, Jones H, Ngan HY and Pecorelli S: FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 70:209–262. 2000. View Article : Google Scholar : PubMed/NCBI
17	Manos MM, Ting Y, Wright DK, et al: The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cell. 7:209–214. 1989.
18	Nakagawa K, Yamamura K, Maeda S and Ichihashi M: Bcl-2 expression in epidermal keratinocytic diseases. Cancer. 74:1720–1724. 1994. View Article : Google Scholar : PubMed/NCBI
19	Serre D, Gurd S, Ge B, et al: Differential allelic expression in the human genome: a robust approach to identify genetic and epigenetic cis-acting mechanisms regulating gene expression. PLoS Genet. 4:e10000062008. View Article : Google Scholar : PubMed/NCBI
20	Keku TO, Vidal A, Oliver S, et al: Genetic variants in IGF-I, IGF-II, IGFBP-3, and adiponectin genes and colon cancer risk in African Americans and Whites. Cancer Causes Control. 23:1127–1138. 2012. View Article : Google Scholar : PubMed/NCBI
21	Dean JP, Sprenger CC, Wan J, et al: Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation. J Clin Endocrinol Metab. 98:E820–E828. 2013. View Article : Google Scholar : PubMed/NCBI
22	Tsilidis KK, Travis RC, Appleby PN, et al: Insulin-like growth factor pathway genes and blood concentrations, dietary protein and risk of prostate cancer in the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). Int J Cancer. 15:495–504. 2013. View Article : Google Scholar
23	Wang Z, Wang Z, Liang Z, et al: Expression and clinical significance of IGF-1, IGFBP-3, and IGFBP-7 in serum and lung cancer tissues from patients with non-small cell lung cancer. Onco Targets Ther. 6:1437–1444. 2013.PubMed/NCBI
24	Savage MO: Insulin-like growth factors, nutrition and growth. World Rev Nutr Diet. 106:52–59. 2013. View Article : Google Scholar : PubMed/NCBI
25	Shen MR, Hsu YM, Hsu KF, et al: Insulin-like growth factor 1 is a potent stimulator of cervical cancer cell invasiveness and proliferation that is modulated by ανβ3 integrin signaling. Carcinogegenesis. 27:962–971. 2006. View Article : Google Scholar
26	Bruchim I and Werner H: Targeting IGF-1 signaling pathways in gynecologic malignancies. Expert Opin Ther Targets. 17:307–320. 2013. View Article : Google Scholar : PubMed/NCBI
27	Mannhard B, Weinzimer SA, Wagner M, et al: Human papillomavirus type 16 E7 oncoprotein binds and inactivates growth-inhibitory insulin-like growth factor binding protein 3. Mol Cell Biol. 20:6483–6495. 2000. View Article : Google Scholar
28	Maloney EK, McLaughlin JL, Dagdigian NE, et al: An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res. 63:5073–5083. 2003.PubMed/NCBI
29	Nakamura K, Hongo A and Kodama J: Down-regulation of the insulin-like growth factor I receptor by antisense RNA can reverse the transformed phenotype of human cervical cancer cell lines. Cancer Res. 60:760–765. 2000.PubMed/NCBI
30	Harris TG, Bruk RD, Yu H, et al: Insulin like-growth factor axis and oncogenic human papillomavirus natural history. Cancer Epidemiol Biomarkers Prev. 17:245–248. 2008. View Article : Google Scholar : PubMed/NCBI
31	Lee SW, Lee SY, Lee SR, et al: Plasma levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in women with cervical neoplasia. J Gynecol Oncol. 21:174–180. 2010. View Article : Google Scholar : PubMed/NCBI
32	Schaffer A, Koushik A, Trottier H, et al: Insulin-like growth factor-I and risk of high-grade cervical intraepithelian neoplasia. Cancer Epidemiol Biomarkers Prev. 16:716–722. 2007. View Article : Google Scholar : PubMed/NCBI
33	Jozefiak A, Pacholska-Bogalska J, Myga-Nowak M, et al: Serum and tissue levels of insulin-like growth factor-I in women with dysplasia and HPV-positive cervical cancer. Mol Med Report. 1:231–237. 2008.
34	Cleveland RJ, Gammon MD, Edmiston SN, et al: IGF1 CA repeat polymorphisms, lifestyle factors and breast cancer risk in the Long Island Breast Cancer Study Project. Carcinogenesis. 27:758–765. 2006. View Article : Google Scholar
35	Missmer SA, Haiman CA and Hunter DJ: A sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer. Int J Cancer. 100:332–336. 2002. View Article : Google Scholar : PubMed/NCBI
36	Fehringer G, Ozcelik H, Knight JA, et al: Association between IGF1 CA microsatellites and mammographic density, anthropometric measures, and circulating IGF-I levels in premenopausal Caucasian women. Breast Cancer Res Treat. 116:413–423. 2009. View Article : Google Scholar
37	DeLellis K, Ingles S, Kolonel L, et al: IGF1 genotype, mean plasma level and breast cancer risk in the Hawaii/Los Angeles multiethnic cohort. British J Cancer. 88:277–282. 2003. View Article : Google Scholar
38	Chen HY, Chan IHS, Sham ALK, et al: Haplotype effect in the IGF1 promoter accounts for the association between microsatellite and serum IGF1 concentration. Clin Endocrinol (Oxf). 74:520–527. 2011. View Article : Google Scholar
39	Jernström H, Sandberg T, Bågeman E, et al: Insulin-like growth factor-1 genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating insulin-like growth factor-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families. Br J Cancer. 14:92:857–866. 2005. View Article : Google Scholar
40	Costalonga EF, Antonini SR, Guerra G Jr, et al: Growth hormone pharmacogenetics: the interactive effect of amicrosatellite in the IGF1 promoter region with the GHR-exon 3 and-202 A/C IGFBP3 variants on treatment outcomes of children with severe GH deficiency. Pharmacogenomics J. 125:439–445. 2012. View Article : Google Scholar
41	Hand BD, Kostek MC, Ferrell RE, et al: Influence of promoter region variants of insulin-like growth factor pathway genes on the strength-training response of muscle phenotypes in older adults. J Appl Physiol. 103:1678–1687. 2007. View Article : Google Scholar : PubMed/NCBI